Real Time Search
CES A80 :
CES 120 :
Total Turn.

Abbisko Therapeutics Announced the Entry into a Licensing Agreement for Pimicotinib (ABSK021) with Merck

2023-12-04 21:05:00

SHANGHAI, Dec. 4, 2023 /PRNewswire/ -- On 4 Dec. 2023, Abbisko Therapeutics announced that it has entered into a licensing agreement with Merck, a leading science and technology company headquartered in Darmstadt, Germany. Under the terms of the agreement, Merck will be granted an exclusive license to commercialize products comprising or containing pimicotinib (ABSK021) for all indications in Chinese mainland, Hong Kong, Macau and Taiwan (the "Licensed Territory"), and Abbisko Therapeutics will retain the exclusive rights to develop pimicotinib within the Licensed Territory. Abbisko Therapeutics has also granted Merck an exclusive option for global commercial rights of pimicotinib, subject to the terms and conditions as agreed between the parties (the "Global Commercialization Option"). In addition, Merck has the option to co-develop pimicotinib in additional indications under certain conditions.

Pursuant to the License Agreement, Abbisko Therapeutics will receive a one-time, non-refundable down payment of US$ 70 million. In the event that Merck exercises the Global Commercialization Option, Merck will pay Abbisko Therapeutics an additional option exercise fee. The aggregate amount of upfront payment, exercising payment, and development and commercialization milestone adds up to US$ 605.5 million, plus a double-digit percentage (%) royalty on actual annual net sales.

Dr. Xu Yao-chang, Chairman of Abbisko Therapeutics, said that "The collaboration with Merck is an important milestone in advancing the global commercialization process of pimicotinib, and provides a new model for the commercialization path of the company's pipeline in the future. We are pleased to collaborate with a leading multinational pharmaceutical company, jointly accelerating the global approval and commercialization pace of pimicotinib, and striving to bring new treatment options to patients as soon as possible."

"We have the opportunity through our partnership with Abbisko to deliver a first-in-class treatment for a critically underserved patient population in China and potentially beyond," said Andrew Paterson, Chief Marketing Officer for the Healthcare business sector of Merck. "Pimicotinib provides an opportunity to address a significant unmet medical need and for us to expand our commercial footprint in oncology in China, the second largest pharmaceutical market in the world."

About Pimicotinib (ABSK021)

Pimicotinib is a novel, orally available, highly selective, and potent small molecule CSF-1R inhibitor, independently developed by Abbisko Therapeutics. It has been granted the breakthrough therapy designation (BTD) and Priority Medicine (PRIME) designation by China NMPA, U.S.FDA, and EMA for the treatment of TGCT patients that are not amenable to surgery. The study is the first global Phase III clinical trial of TGCT conducted simultaneously in China, the U.S., Canada and Europe.

Upon 1-year follow-up, striking improvement in efficacy has been observed with pimicotinib treatment and results were presented at CTOS in November of 2023, with an ORR of 87.5% (28/32, including 3 CR) in the 50 mg QD cohort. The Phase I dose-escalation trial for pimicotinib has been completed in the United States previously.

There is currently no approved drug available in China for TGCT patients, and only one drug has been approved in the U.S.. However, it is only available through the Risk Evaluation and Mitigation Strategy (REMS) Program which is a restricted procedure due to the potential liver injuries it may cause. There are unmet medical needs of TGCT patients in China, the U.S., and Europe.

Abbisko Therapeutics is also actively exploring the clinical potential of pimicotinib in many types of solid tumors, and has obtained approval from NMPA to conduct a Phase II clinical study in chronic graft-versus-host disease and a Phase II clinical study in advanced pancreatic cancer.

As of the date of this announcement, no highly selective CSF-1R inhibitor has been approved in China.

About Abbisko Therapeutics

Founded in April 2016, Abbisko Therapeutics Co., Ltd., a subsidiary of Abbisko Cayman Limited (Stock Code on the Hong Kong Stock Exchange: 2256. HK), is an oncology-focused biopharmaceutical company founded in Shanghai, dedicated to discovering and developing innovative medicines to meet unmet medical needs in China and globally. The Company was established by a group of seasoned drug hunters with rich R&D and managerial expertise from top multinational pharmaceutical companies. Since its founding, Abbisko Therapeutics has built an extensive pipeline of 15 innovative small molecule programs focused on precision oncology and immuno-oncology, including eight clinical stage assets.

Please visit for more information.


PR Newswire News

Lion Enhances OTC Stock Options Services Quality and Efficiency Powered by AI
Autohome Inc. Announces 2023 Q4 and Annual Earnings: New Business Drives Sustained Growth
U Power and Cornerstone Sign MoU to Explore the Application of New Energy Charging Equipment and EV Product Solutions in Hong Kong and Southeast Asia
Autohome Inc. Announces Unaudited Fourth Quarter and Full Year 2023 Financial Results
HKBN and TP-Link Debut One-stop "Priority Plus" Home Wi-Fi Solution
Baidu to Report Fourth Quarter and Fiscal Year 2023 Financial Results on February 28, 2024
"Eddid ONE USA": New Stock Trading App Debuts in the UK, USA, and Canada, Unlocking US Stock Market Opportunities for Global Investors
Futu Clinches Multiple CME Accolades, Affirming Industry Leadership with a Commitment to Deliver Diverse and Flexible Portfolios for Global Investors
Venus Medtech VenusP-Valve transcatheter pulmonic valve replacement system granted Health Canada approval
China Southern Airlines Company Limited Intends to Deregister and Terminate Its Reporting Obligations Under the U.S. Securities Exchange Act of 1934
Innovent Announces Retirement of CFO and Appointment of New CFO
CNOOC Limited Announces Suizhong 36-1/Luda 5-2 Oilfield Secondary Adjustment and Development Project Commences Production
XTransfer Named to the 2023 Deloitte China Technology Fast 50™ Awards Program as the Only Cross-border Payment Platform
13:57:00 Group celebrates Lunar New Year travel boom with 10-fold jump in bookings as visa policies ease
Tan Xuguang Leads Shandong Heavy Industry in Reflecting on 20 Years of Global Expansion at CEO Summit
A Million-Dollar Airdrop Event for Celebrating Live4Well's first 150,000 Users Downloads In the First Month of launching.
World Cancer Day 2024: RemeGen Announces Three Significant Developments in the Global Fight Against Cancer, Narrowing the Care Gap
Weichai Group Advances Toward Becoming a Global Leader in Technological Innovation
Beauty Farm Issues Positive Profit Alert for 2023
DFS Makes History as Douyin Life Service's First Cross-Border Retail Partner, Revolutionizing Chinese Customers' International Luxury Travel Retail Shopping Experience
Back to Top